• 1
    Heidenreich A, Bolla M, Joniau S et al. EAU guidelines on prostate cancer. March 2009. Available at:
  • 2
    Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294: 23844
  • 3
    Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res 1990; 50: 227582
  • 4
    Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate specific antigen. Cancer 1993; 71: 278290
  • 5
    Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 4959
  • 6
    Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 2003; 43: 23340
  • 7
    Goldenberg SL, Gleave ME, Taylor D, Bruchovsky N. Clinical experience with intermittent androgen suppression in prostate cancer: minimum of 3 years' follow-up. Mol Urol 1999; 3: 28792
  • 8
    Spry NA, Kristjanson L, Hooton B et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42: 108392
  • 9
    Bouchot O, Lenormand L, Karam G et al. Intermittent androgen suppression in the treatment of metastatic prostate cancer. Eur Urol 2000; 38: 5439
  • 10
    Klotz L, O'Callaghan CJ, Ding K et al. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 2011; 29 (Suppl. 15): 2925; abstract 4514
  • 11
    Tunn U, Eckhart O, Kienle E, Hillger H. Intermittent androgen deprivation in patients with PSA-relapse after radical prostatectomy – first results of a randomised prospective phase-III clinical trial (AUO study AP06/95). Eur Urol Suppl 2003; 2: 24
  • 12
    de Leval J, Boca P, Yousef E et al. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomised multicenter trial. Clin Prostate Cancer 2002; 1: 16371
  • 13
    Lane TM, Ansell W, Farrugia D et al. Long-term outcomes in patients with prostate cancer managed with intermittent androgen suppression. Urol Int 2004; 73: 11722
  • 14
    Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 126977
  • 15
    Miller K, Steiner U, Lingnau A et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5105]. Presented at American Society of Clinical Oncology; June 1–5, 2007; Chicago, IL, USA
  • 16
    Lukacs B, Comet D, Grange JC, Thibault P. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. Br J Urol 1997; 80: 72230
  • 17
    Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 36576
  • 18
    Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: refining the concept. Urology 1995; 46: 1428
  • 19
    Murphy GP, Slack NH. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1980; 1: 37582
  • 20
    Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 103642
  • 21
    Fayers PM, Aaronson NK, Bjordal K et al. EORTC QLQ-C30 Scoring Manual, 3 edn. Brussels: European Organization for Research and Treatment of Cancer, 2001
  • 22
    Conti PD, Atallah AN, Arruda H et al. Intermittent versus continuous androgen suppression for prostatic cancer. Cochrane Database Syst Rev 2007; (4): CD005009
  • 23
    Loblaw DA, Virgo KS, Nam R et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007; 25: 1596605
  • 24
    Irani J, Celhay O, Hubert J et al. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Eur Urol 2008; 54: 38291
  • 25
    Schasfoort E, Heathcote P, Lock T et al. Intermittent androgen suppression for the treatment of advanced prostate cancer. J Urol 2003; 169 (Suppl. 4): 387; abstract 1483
  • 26
    Hussain M, Goldman B, Tangen C et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 24506
  • 27
    Gleave M, Klotz L, Taneja SS. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. Urol Oncol 2009; 27: 816
  • 28
    Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Lancet 2000; 355: 14918
  • 29
    Seruga B, Tannock IF. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol 2008; 5: 5746
  • 30
    Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005; 7 (Suppl. 5): S3743
  • 31
    Higano C, Shields A, Wood N, Brown J, Tangen C. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression. Urology 2004; 64: 11826
  • 32
    Yu EY, Gulati R, Telesca D et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010; 28: 266873